Rethinking KRAS: From Emerging to Actionable Biomarker In NSCLC

Time: 3:00 pm
day: Day Two Track F

Details:

  • Challenges & opportunities associated with KRAS testing: the current state of biomarker testing in NSCLC
  • Future considerations: keeping up with the evolving complexity of RAS therapy related biomarkers

Speakers: